基于素的补充剂影响IBS-D患者的肠道微生物群组成和活性,可能对症状产生影响:试点研究
Silvia Molino1, Alberto Lerma-Aguilera2, María Marta Piskorz3
1Silvateam Spa, R&D Unit, San Michele Mondovì, Italy. smolino@silvateam.com.
素补充剂改变了腹占主导地位的刺激性肠综合征 (IBS-D) 患者的肠道细菌组成. 这种饮食干预影响了短链脂肪酸的产生,并可能为管理IBS-D症状提供一种新的方法.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 营养科学 营养科学
背景情况:
- 肠道微生物群失生症越来越多地与刺激性肠综合征与腹 (IBS-D) 的病理生理学有关.
- 了解特定的微生物变化及其对宿主生理学的影响,对于开发向疗法至关重要.
研究的目的:
- 为了研究为期8周的基于素的补充剂对IBS-D患者肠道微生物群的组成和活性的影响.
- 确定特定的细菌种群和由素补充剂调节的代谢途径,以及它们与临床症状的相关性.
主要方法:
- 这是一项准实验性的前后前性研究,涉及28名IBS-D患者.
- 使用稀疏的部分最小平方差分分析 (sPLS-DA) 和Boruta算法分析肠道微生物群组成.
- 在便样本中测量短链脂肪酸 (SCFA).
主要成果:
- 没有观察到肠道微生物群的总体α或β多样性的显著变化.
- 发现了特定细菌群体的显著减少,包括Blautia,Eubacterium hallii群和Dorea.
- 乙酸盐和丁酸盐水平增加,而酸盐和甲酸盐水平下降,表明SCFA生产发生了变化.
- 凯特尼细菌的丰富性与疏散相关症状有积极的相关性.
结论:
- 素补充剂在IBS-D患者中选择性调节肠道微生物群组成.
- 观察到的特定细菌种群和SCFA形状的变化表明了改善症状的潜在机制.
- 基于坦宁的干预措施需要进一步研究,作为管理IBS-D的治疗策略.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Irritable Bowel Syndrome III: Medical and Nursing Management
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
